Trilostane NEW

indication

Trilostane can inhibit 3β-dehydrogenase in the process of corticosteroid synthesis, and reduce the synthesis of cortisol and aldosterone. It is clinically used in the treatment of Cushing syndrome (hypercortisolism) and primary hyperaldosteronism, but the therapeutic effect of the treatment of Cushing syndrome (hypercortisolism) is not as good as metiramone. This product also has a significant effect on reducing blood testosterone levels, which may be related to inhibiting its synthesis.

Treatment of advanced breast cancer

Breast cancer is the most common type of cancer in women. At present, for postmenopausal patients with hormone receptor-positive or unknown types of breast cancer, anti-estrogen drugs are recommended as the first choice in clinical treatment, and the effect of this therapy in delaying disease progression and improving survival time has been affirmed and confirmed by a large number of studies. The new drug Trolostam (trade name Modrenal), developed by biotech company Bioenvision and already on the market for the treatment of postmenopausal women whose hormone-selective cancer has spread beyond the breast, slows disease progression in two ways. In hormone-sensitive breast cancer, estrogen promotes cancer cell growth by acting on two receptors, estrogen receptor alpha acting as a cancer accelerator and estrogen receptor beta acting as a brake. Modrenal increased estrogen adsorption to estrogen receptor β, while decreased estrogen receptor alpha. It also acts on another site on the cell's DNA, AP1, to reduce cell proliferation.